PEREGRINE PHARMACEUTICALS INC
10-Q, EX-27, 2000-12-11
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: PEREGRINE PHARMACEUTICALS INC, 10-Q, 2000-12-11
Next: PAB BANKSHARES INC, 11-K, 2000-12-11



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS IS THE LEGEND
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          APR-30-2001
<PERIOD-START>                             MAY-01-2000
<PERIOD-END>                               OCT-31-2000
<CASH>                                       4,132,000
<SECURITIES>                                 6,124,000
<RECEIVABLES>                                  505,000
<ALLOWANCES>                                   280,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                            11,413,000
<PP&E>                                       1,894,000
<DEPRECIATION>                               1,027,000
<TOTAL-ASSETS>                              12,476,000
<CURRENT-LIABILITIES>                        7,023,000
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        96,000
<OTHER-SE>                                   5,327,000
<TOTAL-LIABILITY-AND-EQUITY>                12,476,000
<SALES>                                              0
<TOTAL-REVENUES>                               723,000
<CGS>                                                0
<TOTAL-COSTS>                                5,170,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             177,000
<INCOME-PRETAX>                             (4,624,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (4,624,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (4,624,000)
<EPS-BASIC>                                       (.05)
<EPS-DILUTED>                                     (.05)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission